The effect of the homeopathic remedies Arnica montana and Bellis perennis on mild postpartum bleeding--a randomized, double-blind, placebo-controlled study--preliminary results.

The Center for Integrative Complementary Medicine, Shaare Zedek Medical Center, Jerusalem 91031, Israel.
Complementary Therapies in Medicine (Impact Factor: 2.22). 06/2005; 13(2):87-90. DOI: 10.1016/j.ctim.2005.03.006
Source: PubMed

ABSTRACT To evaluate the effect of Arnica Montana and Bellis perennis on postpartum blood loss.
Double blind, placebo-controlled, randomized, clinical trial.
Department of Gynecology, Shaare Zedek Medical Center, Jerusalem.
Forty parturients were randomized to one of three groups: Arnica montana C6 and Bellis perennis C6 (n=14), Arnica montana C30 and Bellis perennis C30 (n=14), or double placebo (n=12). After 48 h the Arnica/placebo was halted, and patients continued the Bellis/placebo until cessation of lochia.
Hemoglobin levels (Hb) at 48 and 72 h postpartum.
At 72 h postpartum, mean Hb levels remained similar after treatment with homeopathic remedies (12.7 versus 12.4) as compared to a significant decrease in Hb levels in the placebo group (12.7 versus 11.6; p<0.05), in spite of less favorable initial characteristics of the treatment group. The mean difference in Hb levels at 72 h postpartum was -0.29 (95% CI -1.09; 0.52) in the treatment group and -1.18 (95% CI -1.82; -0.54) in the placebo group (p<0.05).
Treatment with homeopathic Arnica montana and Bellis perennis may reduce postpartum blood loss, as compared with placebo.

1 Bookmark
  • [Show abstract] [Hide abstract]
    ABSTRACT: Bellis perennis L. (common daisy) is a medicinal plant in the family Asteraceae. It has been used in the treatment of common cold, wounds, rheumatism and inflammation in traditional medicine. A highly efficient and rapid regeneration system was developed for common daisy for the first time. Field-grown plants and in vitro-grown plantlets were compared in terms of their regeneration capacity. The field-grown plants were found to be much more responsive than the in vitro-grown plantlets when used as explant source. Leaf, pedicel and root explants obtained from field-grown plants, and leaf, petiole and root explants obtained from in vitro-grown plantlets were cultured on Murashige and Skoog's minimal organics medium (MSMO) with various plant growth regulator combinations. The best shoot proliferation was obtained with pedicel explants on media containing 0.5 mg l−1 thidiazuron (TDZ) and 0.5 mg l−1 indole-3-acetic acid (IAA). Plant regeneration was observed trough indirect organogenesis. Regenerated shoots were rooted on MSMO medium containing different concentrations of IAA, indole-3-butyric acid (IBA), naphthalene acetic acid (NAA), and 2,4-dichlorophenoxyacetic acid (2,4-D). IAA (1.0 mg l−1) was determined as the most effective auxin for rooting. Rooted explants were transferred to vermiculite in Magenta containers for acclimatization period. After 2 weeks, they were planted in to plastic pots containing potting soil and maintained in the plant growth room. Approximately 3 months after the transfer to room conditions, the flowering of the regenerated plants could be observed. Quantification of the chosen phenolics in dichloromethane (DCM) and methanol (MeOH) extracts of field-grown leaves and in vitro-grown leaves was performed using high-performance liquid chromatography coupled with tandem mass spectrometry (LC–ESI-MS/MS) method.
    Industrial Crops and Products 07/2013; 48:162–170. · 3.21 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: There are several Cochrane systematic reviews looking at postpartum haemorrhage (PPH) prophylaxis in the third stage of labour and another Cochrane review investigating the timing of prophylactic uterotonics in the third stage of labour (i.e. before or after delivery of the placenta). There are, however, no Cochrane reviews looking at the use of interventions given purely after delivery of the placenta. Ergometrine or methylergometrine are used for the prevention of PPH in the postpartum period (the period after delivery of the infant) after delivery of the placenta in some countries. There are, furthermore, no Cochrane reviews that have so far considered herbal therapies or homeopathic remedies for the prevention of PPH after delivery of the placenta. To assess the effectiveness of available prophylactic interventions for PPH including prophylactic use of ergotamine, ergometrine, methylergometrine, herbal therapies, and homeopathic remedies, administered after delivery of the placenta, compared with no uterotonic agents as well as with different routes of administration for prevention of PPH after delivery of the placenta. We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (30 April 2013), The Food and Drug Administration (FDA) (USA), Medicines and Healthcare Products Regulatory Agency (MHRA) (UK), European Medicines Agency (EMA) (EU), Pharmaceuticals and Medical Devices Agency (PMDA) (Japan), Therapeutic Goods Administration (TGA) (Australia),, Current Controlled Trials, WHO International Clinical Trials Registry Platform (ICTRP), University Hospital Medical Information Network Clinical Trials Registry (UMIN-CTR; Japan), Japan Pharmaceutical Information Center Clinical Trials Information (Japic-CTI; Japan), Japan Medical Association Clinical Trial Registration (JMACCT CTR; Japan) (all on 30 April 2013) and reference lists of retrieved studies SELECTION CRITERIA: All randomised or quasi-randomised controlled trials comparing prophylactic ergotamine, ergometrine, methylergometrine, herbal therapies, and homeopathic remedies (using any route and timing of administration) during the postpartum period after delivery of the placenta with no uterotonic agents or trials comparing different routes or timing of administration of ergotamine, ergometrine, methylergometrine, herbal therapies, and homeopathic remedies, during the postpartum period after delivery of the placenta. Two review authors independently assessed trial eligibility and the methodological quality of trials, extracted data using the agreed form. Data were checked for accuracy. Five randomised studies involving 1466 women met the inclusion criteria. All studies were classified as having an unclear risk of bias. Two studies (involving 1097 women) compared oral methylergometrine with a placebo, and one (involving 171 women) compared oral methylergometrine with Kyuki-chouketsu-in, a Japanese traditional herbal medicine. The remaining two studies (involving 198 women) did not report the outcomes of interest for this review. None of the included studies reported primary outcomes prespecified in the review protocol (blood loss of 1000 mL or more over the period of observation, maternal death or severe morbidity). Overall, there was no clear evidence of differences between groups in the following PPH outcomes: blood loss of 500 mL or more (risk ratio (RR) 1.45; 95% confidence interval (CI) 0.39 to 5.47, two studies), amount of lochia during the first 72 hours of the puerperium (mean difference (MD) -25.00 g; 95% CI -69.79 to 19.79, one study), or amount of lochia by four weeks postpartum (MD -7.00 g; 95% CI -23.99 to 9.99).The Japanese study with a relatively small sample size comparing oral methylergometrine with a Japanese traditional herbal medicine found that oral methylergometrine significantly increased the blood haemoglobin concentration at day one postpartum (MD 0.50 g/dL; 95% CI 0.11 to 0.89) compared to herbal medicine. Adverse events were not well-reported in the included studies. We did not find any studies comparing homeopathic remedies with either a placebo or no treatment. There was insufficient evidence to support the use of prophylactic oral methylergometrine given after delivery of the placenta for the prevention of PPH. Additionally, the effectiveness of prophylactic use of herbal medicine or homeopathic remedies for PPH is still unclear as we could not find any clear evidence. Trials to assess the effectiveness of herbal medicines and homeopathic remedies in preventing PPH are warranted.
    Cochrane database of systematic reviews (Online) 11/2013; 11:CD009328. · 5.94 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Abstract Context: Bellis perennis L. (Asteraceae) (common daisy) is a herbaceous perennial plant known as a traditional wound herb; it has been used for the treatment of bruises, broken bones, and wounds. Bellis perennis has also been used in the treatment of headache, common cold, stomachache, eye diseases, eczema, skin boils, gastritis, diarrhea, bleeding, rheumatism, inflammation, and infections of the upper respiratory tract in traditional medicine. Objective: Antitumor activities of different fractions of B. perennis flowers at different concentrations were evaluated and through bioassay-guided fractionation and isolation procedures a saponin derivative (1) was isolated from the active fraction obtained from the n-butanol extract of flowers of the title plant by column chromatography. Materials and methods: Antitumor activities of different fractions of B. perennis flowers at different concentrations were evaluated using Potato Disc Tumor Induction Bioassay. Structure elucidation of 1 was accomplished by spectroscopic methods [1D- and 2D-NMR, and LC-ESI(APCI)-TOF-MS(MSn)]. Results: The present study showed the antitumor activity of fractions obtained from B. perennis flowers for the first time. The most active fraction showed 99% tumor inhibition at 3000 mg/L. An oleanane-type saponin was isolated through bioassay-guided studies. Discussion and conclusion: Through antitumoral bioassay-guided fractionation and isolation procedures, 1 was isolated from the active fraction of B. perennis. The detailed NMR data of compound 1 is given for the first time.
    Pharmaceutical Biology 03/2014; · 1.21 Impact Factor


Available from
May 30, 2014